Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical ...

Aaron Lazar received his first-ever Grammy nomination on Friday, Nov. 8 for his debut album, 'Impossible Dream.' It was an ...

New research supports brain cell transplantation as a treatment for some neurological disorders. A team from McGill ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

He introduced ticket prices that couldn’t be beat, but asked fliers to pay extra for nearly everything, including water, ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...

The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...